Brain Edema Risk May Be Lower With Modified Donanemab Dosing
An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still maintained sufficient amyloid reduction in early Alzheimer’s disease, the phase IIIb TRAILBLAZER-ALZ 6 study showed. At week 24, the frequency of amyloid-related imaging abnormalities with edema and effusion (ARIA-E) was 23.7% for the standard dosing …
Brain Edema Risk May Be Lower With Modified Donanemab Dosing Read More »